MX2018001530A - Anticuerpos anti-pd-l1 novedosos. - Google Patents
Anticuerpos anti-pd-l1 novedosos.Info
- Publication number
- MX2018001530A MX2018001530A MX2018001530A MX2018001530A MX2018001530A MX 2018001530 A MX2018001530 A MX 2018001530A MX 2018001530 A MX2018001530 A MX 2018001530A MX 2018001530 A MX2018001530 A MX 2018001530A MX 2018001530 A MX2018001530 A MX 2018001530A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- block
- novel anti
- ligand
- expressing
- Prior art date
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación provee anticuerpos monoclonales contra la proteína ligando 1 de muerte celular programada (PD-L1), que puede bloquear la unión de PD-L1 a PD-1 y por lo tanto bloquear la función inhibitoria de PD-L1 sobre células T que expresan PD-1. Los anticuerpos de la divulgación proveen agentes muy potentes para el tratamiento de muchos cánceres mediante la modulación de la función inmunitaria humana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/086216 WO2017020291A1 (en) | 2015-08-06 | 2015-08-06 | Novel anti-pd-l1 antibodies |
| PCT/CN2016/093560 WO2017020858A1 (en) | 2015-08-06 | 2016-08-05 | Novel anti-pd-l1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001530A true MX2018001530A (es) | 2018-08-01 |
Family
ID=57942317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001530A MX2018001530A (es) | 2015-08-06 | 2016-08-05 | Anticuerpos anti-pd-l1 novedosos. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10981995B2 (es) |
| EP (1) | EP3332006B1 (es) |
| JP (2) | JP7066614B2 (es) |
| KR (1) | KR20180037222A (es) |
| AU (1) | AU2016301718B2 (es) |
| BR (1) | BR112018002428A2 (es) |
| CA (1) | CA2993272A1 (es) |
| DK (1) | DK3332006T5 (es) |
| ES (1) | ES2966890T3 (es) |
| FI (1) | FI3332006T3 (es) |
| HK (1) | HK1257164A1 (es) |
| HR (1) | HRP20231664T1 (es) |
| HU (1) | HUE064563T2 (es) |
| IL (1) | IL256803B2 (es) |
| LT (1) | LT3332006T (es) |
| MX (1) | MX2018001530A (es) |
| PT (1) | PT3332006T (es) |
| RS (1) | RS64977B1 (es) |
| RU (1) | RU2736151C2 (es) |
| SA (1) | SA518390862B1 (es) |
| SI (1) | SI3332006T1 (es) |
| WO (2) | WO2017020291A1 (es) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| EP3497128A2 (en) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anti-icos antibodies |
| KR20240019398A (ko) | 2016-10-28 | 2024-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법 |
| CN110072890B (zh) | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JP7458188B2 (ja) | 2017-03-31 | 2024-03-29 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| RU2665790C1 (ru) * | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| CN118356488A (zh) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| KR20200010500A (ko) | 2017-05-30 | 2020-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체, pd-1 경로 억제제, 및 면역요법제의 조합을 포함하는 조성물 |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| US11566073B2 (en) | 2017-06-01 | 2023-01-31 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-PD-1 antibody |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| CN111247169A (zh) | 2017-10-15 | 2020-06-05 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| KR20200084880A (ko) | 2017-11-06 | 2020-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2019094265A1 (en) * | 2017-11-10 | 2019-05-16 | Armo Biosciences, Inc. | Pd1 polypeptide binding molecules |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| CA3078849A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
| US20210363242A1 (en) | 2018-01-16 | 2021-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| CA3096287A1 (en) | 2018-01-22 | 2019-07-25 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| BR112020014574A2 (pt) | 2018-01-22 | 2020-12-08 | Bristol-Myers Squibb Company | Composições e métodos para o tratamento do câncer |
| US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| EP3774911A1 (en) | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US12110337B2 (en) | 2018-04-04 | 2024-10-08 | Bristol-Myers Squibb Company | Anti-CD27 antibodies and uses thereof |
| WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| AU2019275737A1 (en) | 2018-06-01 | 2021-01-21 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
| US20210238287A1 (en) | 2018-07-26 | 2021-08-05 | Bristol-Myers Squibb Company | LAG-3 Combination Therapy for the Treatment of Cancer |
| EP3829639A4 (en) | 2018-07-31 | 2022-06-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule |
| JP7488534B2 (ja) * | 2018-08-20 | 2024-05-22 | １グローブ バイオメディカル カンパニー， リミテッド | 新規ながん免疫療法抗体組成物 |
| KR20210072059A (ko) | 2018-10-09 | 2021-06-16 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 항-MerTK 항체 |
| WO2020081928A1 (en) | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
| EP3870609A1 (en) | 2018-10-23 | 2021-09-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| SG11202104969RA (en) | 2018-11-16 | 2021-06-29 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
| EP3902563A4 (en) * | 2018-12-27 | 2022-12-28 | Gigagen, Inc. | ANTI-PD-L1 BINDING PROTEINS AND METHODS OF USE THEREOF |
| WO2020198672A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2020198676A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| JP2022534981A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよび組み合わせ治療 |
| EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| US20220213195A1 (en) * | 2019-06-10 | 2022-07-07 | Shandong Boan Biotechnology Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGFß AND USE THEREOF |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN113795510A (zh) * | 2019-08-29 | 2021-12-14 | 荣昌生物制药(烟台)股份有限公司 | 抗pd-l1抗体及其应用 |
| CA3153777A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| AU2020353079A1 (en) | 2019-09-25 | 2022-04-14 | Bristol-Myers Squibb Company | Composite biomarker for cancer therapy |
| US20220348664A1 (en) * | 2019-09-26 | 2022-11-03 | WuXi Biologics Ireland Limited | A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof |
| JP2022553821A (ja) | 2019-11-05 | 2022-12-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍ－タンパク質アッセイおよびその使用 |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| CA3160479A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| JP2023500385A (ja) * | 2019-11-11 | 2023-01-05 | シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド | 医薬組合せ物およびその使用 |
| WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
| KR20220118481A (ko) | 2019-12-19 | 2022-08-25 | 브리스톨-마이어스 스큅 컴퍼니 | Dgk 억제제 및 체크포인트 길항제의 조합물 |
| WO2021152548A1 (en) | 2020-01-30 | 2021-08-05 | Benitah Salvador Aznar | Combination therapy for treatment of cancer and cancer metastasis |
| JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１０およびその使用 |
| KR20220151195A (ko) | 2020-03-06 | 2022-11-14 | 오엔에이 테라퓨틱스 에스.엘. | 항-cd36 항체 및 암을 치료하기 위한 이의 용도 |
| US20230119066A1 (en) | 2020-03-23 | 2023-04-20 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
| EP4132969A4 (en) | 2020-04-07 | 2024-05-01 | Fred Hutchinson Cancer Center | ANTI-MESOTHELIN ANTIGEN BINDING MOLECULES AND THEIR USES |
| WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| CN116490208A (zh) * | 2020-08-06 | 2023-07-25 | 史坦利科西斯治疗有限责任公司 | Il-8抗体及其使用方法 |
| AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| US20230374064A1 (en) | 2020-10-05 | 2023-11-23 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| US20240101666A1 (en) | 2020-10-23 | 2024-03-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| IL303648A (en) | 2020-12-28 | 2023-08-01 | Bristol Myers Squibb Co | Antibody preparations and methods of using them |
| CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| IL309934A (en) | 2021-07-30 | 2024-03-01 | Ona Therapeutics S L | Anti-CD36 antibodies and their use for cancer treatment |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202321296A (zh) * | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| IL314050A (en) | 2022-01-26 | 2024-09-01 | Bristol Myers Squibb Co | Combined treatment method for hepatocellular carcinoma |
| CN118765284A (zh) | 2022-02-25 | 2024-10-11 | 百时美施贵宝公司 | 结直肠癌的组合疗法 |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| WO2023230624A2 (en) * | 2022-05-27 | 2023-11-30 | Taipei Medical University | Epha2-targeting antibodies and their applications in cancer treatment |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| JP2024013645A (ja) | 2022-07-20 | 2024-02-01 | セイコーエプソン株式会社 | 微細化装置 |
| EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
| CN115925947B (zh) * | 2022-09-27 | 2023-08-22 | 上海百英生物科技股份有限公司 | 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟 |
| WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
| WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| WO2024116140A1 (en) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024150177A1 (en) | 2023-01-11 | 2024-07-18 | Advesya | Treatment methods for solid tumors |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
| EP2192131A1 (en) | 1992-08-21 | 2010-06-02 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US6048911A (en) | 1997-12-12 | 2000-04-11 | Borden Chemical, Inc. | Coated optical fibers |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CN101104640A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
| CN101104540A (zh) | 2006-07-13 | 2008-01-16 | 康那香企业股份有限公司 | 污水处理系统及其方法 |
| HUE030139T2 (en) | 2006-12-27 | 2017-04-28 | Univ Emory | Preparations and procedures for treating inflammations |
| AU2008259939B2 (en) | 2007-06-01 | 2014-03-13 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| CN102245640B (zh) | 2008-12-09 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| MX359551B (es) | 2009-11-24 | 2018-10-02 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
| JP6302895B2 (ja) * | 2012-05-02 | 2018-03-28 | スパイバー テクノロジーズ アーベーＳｐｉｂｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ａｂ | 親和性リガンドとして免疫グロブリン断片を組み込んだクモ糸融合タンパク質の構造 |
| BR112014029883B1 (pt) | 2012-05-31 | 2023-10-24 | Sorrento Therapeutics Inc. | Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1 |
| US9626778B2 (en) | 2012-06-01 | 2017-04-18 | The Johns Hopkins University | Information propagation in prior-image-based reconstruction |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014124227A1 (en) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| KR20210143932A (ko) | 2013-09-11 | 2021-11-29 | 메디뮨 리미티드 | 종양 치료용 항-ｂ7-ｈ1 항체 |
| EA035037B1 (ru) | 2013-12-12 | 2020-04-21 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение |
| HUE054873T2 (hu) * | 2014-02-10 | 2021-10-28 | Merck Patent Gmbh | Célzott TGF-béta-gátlás |
| RU2017108173A (ru) | 2014-08-14 | 2018-09-17 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 |
-
2015
- 2015-08-06 WO PCT/CN2015/086216 patent/WO2017020291A1/en active Application Filing
-
2016
- 2016-08-05 IL IL256803A patent/IL256803B2/en unknown
- 2016-08-05 PT PT168323467T patent/PT3332006T/pt unknown
- 2016-08-05 EP EP16832346.7A patent/EP3332006B1/en active Active
- 2016-08-05 HR HRP20231664TT patent/HRP20231664T1/hr unknown
- 2016-08-05 BR BR112018002428A patent/BR112018002428A2/pt active Search and Examination
- 2016-08-05 ES ES16832346T patent/ES2966890T3/es active Active
- 2016-08-05 FI FIEP16832346.7T patent/FI3332006T3/fi active
- 2016-08-05 LT LTEPPCT/CN2016/093560T patent/LT3332006T/lt unknown
- 2016-08-05 HU HUE16832346A patent/HUE064563T2/hu unknown
- 2016-08-05 AU AU2016301718A patent/AU2016301718B2/en active Active
- 2016-08-05 CA CA2993272A patent/CA2993272A1/en active Pending
- 2016-08-05 WO PCT/CN2016/093560 patent/WO2017020858A1/en active Application Filing
- 2016-08-05 MX MX2018001530A patent/MX2018001530A/es unknown
- 2016-08-05 SI SI201631777T patent/SI3332006T1/sl unknown
- 2016-08-05 RS RS20231228A patent/RS64977B1/sr unknown
- 2016-08-05 JP JP2018526289A patent/JP7066614B2/ja active Active
- 2016-08-05 RU RU2018107658A patent/RU2736151C2/ru active
- 2016-08-05 US US15/749,783 patent/US10981995B2/en active Active
- 2016-08-05 DK DK16832346.7T patent/DK3332006T5/da active
- 2016-08-05 KR KR1020187005942A patent/KR20180037222A/ko not_active Application Discontinuation
-
2018
- 2018-02-01 SA SA518390862A patent/SA518390862B1/ar unknown
- 2018-12-06 HK HK18115668.9A patent/HK1257164A1/zh unknown
-
2021
- 2021-03-12 US US17/200,374 patent/US20210269528A1/en active Pending
-
2022
- 2022-04-27 JP JP2022072902A patent/JP2022115897A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518390862B1 (ar) | Pd-l1 أجسام مضادة ضد | |
| MX2022006447A (es) | Anticuerpos anti-pd-1 novedosos. | |
| MX2021006786A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
| MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
| ZA202310395B (en) | Substituted inhibitors of menin-mll and methods of use | |
| PH12018501955A1 (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| MX2018003689A (es) | Proteinas de union a pd-1 y metodos para usarlas. | |
| NZ738008A (en) | Tigit-binding agents and uses thereof | |
| MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
| WO2016106159A8 (en) | Anti-pd-1 antibodies | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| MY186712A (en) | Methods and compositions for inhibiting the interaction of menin with mll proteinss | |
| NZ734256A (en) | Use of plinabulin in combination with immune checkpoint inhibitors | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| MX2018012651A (es) | Composiciones que comprenden coformulacion de anticuerpos anti-ligando-1 de muerte celular programada (pd-l1) y anti-antigeno-4 asociado a linfocitos t citotoxicos (ctla-4). | |
| SA521422089B1 (ar) | c أجسام مضادة مكتسبة للسمة البشرية ضد مجموعة | |
| MX2018011035A (es) | Anticuerpos-anti-mica. | |
| MX2021004036A (es) | Anticuerpos biespecíficos dirigidos a exosomas. | |
| WO2018138032A3 (en) | NKp46 BINDING AGENTS | |
| NZ768427A (en) | Anti-cd137 antibodies for combination with anti-pd-l1 antibodies | |
| MX2021002077A (es) | Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: WUXI BIOLOGICS (SHANGHAI) CO. LTD. |